Pioneering AI provider for radiology annalise.ai appoints proven global healthcare leader as CEO, launches official US team after FDA approval

Seasoned health technology executive Lakshmi Gudapakkam becomes CEO and former HCA Healthcare, Inc. executive Dr Rick Abramson appointed chief physician.

New leadership team to drive global expansion of the world’s first comprehensive AI radiology platform and access to the US.

CADt FDA Approvals for Annalize Enterprise CXR to Open New Opportunities for US Clinicians.

SYDNEYJuly 5, 2022 /PRNewswire/ — annalise.ai, the global AI radiology company with a rapidly growing presence in Asia-PacificEurope and the United Kingdomtoday announced the appointment of veteran healthcare technology executives Lakshmi Gudapakkam as Chief Executive Officer and Clinical Strategist Dr. Rick Abramson as Chief Medical Officer. With the new appointments, annalise.ai expects to further accelerate its global market presence and access to the US market following recent FDA approvals for part of its comprehensive radiology AI product.

With a mission to help one million patients every day, annalise.ai combines advanced AI with clinical expertise to bring comprehensive AI products to market quickly, with state-of-the-art performance and a focus on clinical success. Formed in 2019 as a joint venture between healthcare AI platform harrison.ai and I-MED Radiology Network, Australia’s largest diagnostic imaging network, the company is focused on the rapid development and commercialization of comprehensive AI products to improve patient care.

annalise.ai products have been used to help more than one million patients since launch. Annalize Enterprise CXR, the world’s first comprehensive decision-support AI solution for chest X-rays, is already in clinical use at more than 400 sites in Australia and the UK and accessible to one in four Australian radiologists. A recent peer-reviewed diagnostic accuracy study published in The Lancet Digital Health found that Annalize Enterprise CXR improved radiologists’ diagnostic accuracy based on 102 chest radiographs (CXR)*.

Company has clinical use approval for Annalize Enterprise CXR in Australiathe United KingdomEuropeSouth East Asiaand New Zealand, and is expanding its products into new geographies. Earlier this year, Annalize Enterprise CXR CADt received FDA approval for use in triage and reporting of pneumothorax and tension pneumothorax on chest radiographs.

The appointment of Lakshmi Gudapakkam as CEO will help accelerate expansion plans globally and in the US, along with the development of new AI radiology tools. Mr. Gudapakkam brings a wealth of health tech expertise, where he served more than 20 years in senior global technology and business leadership roles at GE Healthcare & Philips Healthcare and the last four years at Quest Diagnostics, as their Vice President and General Manager for their East region.

During his time at GE Healthcare, Mr. Gudapakkam led major global teams in the US, CanadaEuropeIndiaChina and Australia in major, pioneering product development for radiologic imaging, cardiac imaging and healthcare informatics.

At Philips Healthcare, he oversaw breakthrough products in CT & Advanced Visualization Imaging. Later, Mr. Gudapakkam moved into leadership roles in global business, expanding Philips Healthcare’s footprint around the world ChinaIndia and the rest of Asia† Mr. Gudapakkam led major global companies including the Global Value Segment business, the Global X-ray & Mammography business and later a portfolio of global companies including CT, Molecular Imaging, X-ray & Mammography.

During his time at Quest Diagnostics, Mr. Gudapakkam oversaw the expansion of the company’s diagnostic services through laboratory management partnerships, managed the scale-up of tests during the COVID pandemic period, while leading key transformation programs including IT standardization systems and the development of a megalab in Clifton, New Jersey and consolidating lab testing in the Eastern region.

Throughout his career, Mr. Gudapakkam has worked closely with both technologists and clinical experts in radiology and imaging, providing a broad network and the perfect blend of skills and business acumen to help translate complex technologies into specialized healthcare.

By further strengthening its global leadership bank, Rick Abramson, MD, MHCDS, FACR, joins the annalise.ai team as CMO and will be responsible for guiding the company’s clinical roadmap for international expansion. dr. Abramson, a US-based physician leader and board-certified radiologist, has more than 25 years of healthcare experience, including previous roles in clinical practice, academic research, policy development, and management. Formerly corporate vice president of the radiology service line at HCA Healthcare, Inc., Dr. Abramson’s strategic development of radiology and artificial intelligence businesses across HCA’s network of 185 hospitals in the US and UK.

In his new role at annalise.ai, Dr. Help Abramson foster stakeholder partnerships with healthcare providers, technology developers and regulators around the world.

Both Mr Gudapakkam and Dr Abramson will be based in the United Statessupported by a strong global team of hundreds of annalise.ai employees across Australiathe UK, Europe and now the US with expected growth in other locations in line with expected business growth.

Annalize.ai Founding CEO, who played an integral role in the creation and success of the joint venture, Dimitry Tran will continue to serve as director of the board of directors and part of the harrison.ai team. dr. Aengus Tran, co-founder and CEO of harrison.ai, will also continue as Chief AI Officer of annalise.ai.

Dimitry TranFounding CEO and Board Director of annalise.ai, said: “We started creating an advanced AI solution almost three years ago that will enable clinicians to make faster, more accurate decisions about radiological diagnoses. With the hard work of our global team, we have built an extremely strong and sustainable company with a proven model and a global roadmap.To truly achieve our goals and grow globally, we must enter the next stage of our maturity and strategy.I am pleased to welcome Mr. Gudapakkam and Dr. Abramson to the annalise.ai- team to lead the company through this next phase of expansion and help fulfill our mission of helping a million people every day.”

Clare Battellinopresident of annalise.ai, said: “Lakshmi is an exceptional executive and someone we are very excited to help advance the vision and strategy of annalise.ai into our next stage of growth as a company. His approach to innovation, deep expertise in the healthtech space and established network will help catapult annalise.ai into the future. Dimitry’s contribution to annalise.ai cannot be overstated as he has tirelessly guided the formation and growth of annalise.ai from its inception. We are delighted to have him pivotal in the future. will continue to have input from annalise.ai as director of the board.”

dr. Aengus Tran, co-founder and CEO of harrison.ai, said: “By leveraging the AI ​​capabilities of Harrison.ai and its leading clinical partners I-MED, annalise.ai has become increasingly powerful in bringing its groundbreaking AI products to the market for radiology. Lakshmi is well positioned to help us achieve those goals and will ensure we have the right skills and global connections to expand our reach into new countries, new regulatory areas and new radiology products.”

Lakshmi Gudapakkam, Chief Executive Officer of annalise.aisaid: “To meet the growing demand for our global healthcare system, we need smart tools that help specialists diagnose and treat patients more effectively and accurately. The annalise.ai team has shown an amazing ability to not only rapidly but do it with clinical experts and patients at the forefront. I’m excited to join the team and contribute to reaching our goal of helping one million patients every day.”

*Study Citation: Assisted Radiologist Performance — The deep learning model statistically significantly improved radiologist classification accuracy for 102 (80%) of 127 clinical findings, was statistically non-inferior for 19 (15%) findings, and no findings were shown a decrease in accuracy when radiologists used the deep learning model. Unassisted radiologists had a macromean mean AUC of 0.713 (0.645-0.785) for all findings compared to 0.957 (0.954-0.959) for the model alone.

Contact: Virginie Cosentino[email protected]

SOURCE annalise.ai

Leave a Comment

Your email address will not be published.